IPSC
Century Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.86
−1.06%Sep 15, 2026, 23:52 UTC
Douglas Carr, Senior Vice President of Finance & Operations at Century Therapeutics, sold 1,658 shares of the company's common stock on September 14, 2026, at $1.93 per share for a total of $3,199 to cover tax withholding obligations tied to vesting restricted stock units.
Source:Sep 9, 2026, 20:19 UTC
Century Therapeutics, Inc. appointed Joseph Truitt as a member of its Board of Directors, effective September 9, 2026, and granted him an initial option award to purchase 148,000 shares of the company's common stock.
Aug 12, 2026, 12:00 UTC
Century Therapeutics is on track to advance CNTY-308, a CD19-targeted CAR-iT cell therapy with Allo-Evasion 5.0, into the clinic this year.
Source:Aug 12, 2026, 12:00 UTC
Century Therapeutics completed a pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy for type 1 diabetes, and plans to submit an IND in the fourth quarter of 2026.
Source:Aug 12, 2026, 12:00 UTC
Century Therapeutics reported financial results for the second quarter ended June 30, 2026, with cash, cash equivalents, and investments of $197.2 million as of June 30, 2026, and a cash runway into the first quarter of 2029.
Source: